Fig. 2 | Scientific Reports

Fig. 2

From: Efficacy and safety of Latilactobacillus sakei LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial

Fig. 2

Improvements in primary efficacy endpoints related to LB-P12 in the PP group. This figure summarizes the changes in primary efficacy endpoints in the PP group, including the WOMAC total score, pain, stiffness, and physical function subcategories, over 12 weeks between the control and treatment groups.

Back to article page